NasdaqCM - Nasdaq Real Time Price USD
Avalo Therapeutics, Inc. (AVTX)
Tune into live earnings calls Now streaming directly on quote pages.
4.0600
-0.2900
(-6.67%)
At close: May 9 at 4:00:00 PM EDT
4.0581
-0.00
(-0.05%)
After hours: May 9 at 7:50:51 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Garry A. Neil M.D. | President, CEO & Director | 1.03M | -- | 1954 |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer | 678.12k | -- | 1965 |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board | -- | -- | 1939 |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board | -- | -- | 1965 |
| Mr. Paul C. Varki J.D., M.P.H | Chief Legal Officer | -- | -- | 1973 |
| Dr. Lisa Hegg Ph.D. | Senior Vice President of Program Management, Business Development & Corporate Infrastructure | -- | -- | -- |
| Ms. Colleen Matkowski | Senior Vice President of Global Regulatory Affairs & Quality Assurance | -- | -- | -- |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations | -- | -- | -- |
| Ms. Jennifer Riley | Chief Strategy Officer | -- | -- | 1975 |
Avalo Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Corporate Governance
Avalo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Avalo Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
TVGNW Tevogen Bio Holdings Inc.
0.0440
-6.38%
ORKA Oruka Therapeutics, Inc.
9.54
-2.15%
PVLA Palvella Therapeutics, Inc.
22.77
-1.17%
ANAB AnaptysBio, Inc.
19.59
+0.05%
ELVN Enliven Therapeutics, Inc.
18.42
-1.13%
IRON Disc Medicine, Inc.
44.24
-0.11%
ARTV Artiva Biotherapeutics, Inc.
2.0800
-4.59%
PEPG PepGen Inc.
1.5000
-2.60%
ZURA Zura Bio Limited
1.2100
-3.97%
EWTX Edgewise Therapeutics, Inc.
14.58
-0.82%